author-photo

Carol Cronenberger

Pfizer

20

Papers

171

Citations

Citation Trend

Filter By

Papers (14) Sort By

Journal Conference Others

Randomized, Open-Label, Single-Dose, Parallel-Group Pharmacokinetic Study of PF-06410293 (adalimumab-afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects.

2021 Clinical pharmacology in drug development
Show All
- Source
- Cite
- Save
Citations (0)
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293.

2021 RMD Open
Show All
- Source
- Cite
- Save
Citations (2)
Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial

2020 BioDrugs
Show All
- Source
- Cite
- Save
Citations (2)
Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?

2020 BioDrugs
Show All
- Source
- Cite
- Save
Citations (4)
Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer

2019 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (2)
Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54

2019 RMD Open
Show All
- Source
- Cite
- Save
Citations (13)
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

2018 Arthritis Research & Therapy
Show All
- Source
- Cite
- Save
Citations (25)
FRI0137 Efficacy, safety and immunogenicity from week 30 to week 54 in a randomised, double-blind phase iii study comparing a proposed infliximab biosimilar (PF-06438179/GP1111) with reference infliximab

2018 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (3)
Extension Study of PF‐05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis

2018 Arthritis Care and Research
Show All
- Source
- Cite
- Save
Citations (17)
Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy

2017 Alzheimer's & Dementia: Translational Research & Clinical Interventions
Show All
- Source
- Cite
- Save
Citations (25)